Targeted alteration of dietary n-3 and n-6 fatty acids for the treatment of chronic headaches: a randomized trial - PubMed (original) (raw)
Randomized Controlled Trial
. 2013 Nov;154(11):2441-2451.
doi: 10.1016/j.pain.2013.07.028. Epub 2013 Jul 22.
Keturah R Faurot, Daisy Zamora, Chirayath M Suchindran, Beth A MacIntosh, Susan Gaylord, Amit Ringel, Joseph R Hibbeln, Ariel E Feldstein, Trevor A Mori, Anne Barden, Chanee Lynch, Rebecca Coble, Emilie Mas, Olafur Palsson, David A Barrow, Douglas J Mann
Affiliations
- PMID: 23886520
- PMCID: PMC3850757
- DOI: 10.1016/j.pain.2013.07.028
Randomized Controlled Trial
Targeted alteration of dietary n-3 and n-6 fatty acids for the treatment of chronic headaches: a randomized trial
Christopher E Ramsden et al. Pain. 2013 Nov.
Abstract
Omega-3 and n-6 fatty acids are biosynthetic precursors to lipid mediators with antinociceptive and pronociceptive properties. We conducted a randomized, single-blinded, parallel-group clinical trial to assess clinical and biochemical effects of targeted alteration in dietary n-3 and n-6 fatty acids for treatment of chronic headaches. After a 4-week preintervention phase, ambulatory patients with chronic daily headache undergoing usual care were randomized to 1 of 2 intensive, food-based 12-week dietary interventions: a high n-3 plus low n-6 (H3-L6) intervention, or a low n-6 (L6) intervention. Clinical outcomes included the Headache Impact Test (HIT-6, primary clinical outcome), Headache Days per month, and Headache Hours per day. Biochemical outcomes included the erythrocyte n-6 in highly unsaturated fatty acids (HUFA) score (primary biochemical outcome) and bioactive n-3 and n-6 derivatives. Fifty-six of 67 patients completed the intervention. Both groups achieved targeted intakes of n-3 and n-6 fatty acids. In intention-to-treat analysis, the H3-L6 intervention produced significantly greater improvement in the HIT-6 score (-7.5 vs -2.1; P<0.001) and the number of Headache Days per month (-8.8 vs -4.0; P=0.02), compared to the L6 group. The H3-L6 intervention also produced significantly greater reductions in Headache Hours per day (-4.6 vs -1.2; P=0.01) and the n-6 in HUFA score (-21.0 vs -4.0%; P<0.001), and greater increases in antinociceptive n-3 pathway markers 18-hydroxy-eicosapentaenoic acid (+118.4 vs +61.1%; P<0.001) and 17-hydroxy-docosahexaenoic acid (+170.2 vs +27.2; P<0.001). A dietary intervention increasing n-3 and reducing n-6 fatty acids reduced headache pain, altered antinociceptive lipid mediators, and improved quality-of-life in this population.
Keywords: Clinical trial; Headache; Migraine; Omega-3; Omega-6.
Published by Elsevier B.V.
Conflict of interest statement
Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.
Conflict of interest statement
The authors declare that they have no competing interests. The authors alone are responsible for the content and writing of the article.
Figures
Fig. 1
Proposed mechanisms linking targeted alterations in n-3 and n-6 fatty acids with pain reduction. This figure summarizes hypothetical mechanisms linking n-3 and n-6 fatty acids to pain reduction, including representative mediators measured in the present trial (9-HODE and Resolvin D2) as well as mediators that were not measured in this trial (Prostaglandin E2 and Resolvin E1). (A) Targeted dietary alterations increase the abundance of n-3 EPA and DHA (blue) and decrease the abundance of n-6 LA and AA (red) in fatty acid precursor pools, including the membranes of endothelial cells, platelets, immune cells, glia, myelin, and neurons. (B) These changes in precursor abundance alter the concentrations of n-3 and n-6 derived antinociceptive and pronociceptive mediators, including E- and D-series resolvins, maresins, prostaglandins, endovanilloids, and endocannabinoids. (C) Changes in the milieu of lipid mediators alter the activities of receptors involved in pain signaling, including the vanilloid receptor (TRPV1) and several G-protein coupled receptors (eg, E-prostanoid receptors, resolvin receptors, cannabinoid receptors). (D) Increases in antinociceptive mediators and decreases in pronociceptive mediators reduce pain signaling in the trigeminovascular system and central pain signaling pathways. EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; LA, linoleic acid; AA, arachidonic acid; 9-HODE, 9-hydroxy-octadecadienoic acid.
Fig. 2
CONSORT trial profile.
Fig. 3
Mean daily Headache Hours by dietary intervention group. Graph depicts the average number of Headache Hours calculated for each day according to intervention group. A Loess smoothing procedure was employed to visualize trends. Participants in the 2 groups provided equivalent amounts of Headache Diary data after randomization (2145 total days of records in the L6 group and 2175 in the H3-L6 group).
Fig. 4
Change in medication use over the course of the intervention by diet group. Acute medications included vasoactive abortive medications, acute opioids, and nonsteroidal antiinflammatory drugs; Adjunctive medications included antiemetics, anxiolytics, sleep aids/hypnotics, and muscle relaxants. All changes depicted in Fig. 4 were significantly changed compared to baseline. There was no significant change in the use of Preventive medications (eg, anticonvulsants, antidepressants, vasoactive preventives, long-acting opiates) over time in either group.
Comment in
- Dietary control of chronic headache: involvement of pro-resolution lipid mediators.
Van De Ven T, Ji RR. Van De Ven T, et al. Pain. 2013 Nov;154(11):2247-2248. doi: 10.1016/j.pain.2013.08.006. Epub 2013 Aug 15. Pain. 2013. PMID: 23954765 No abstract available.
Similar articles
- Dietary alteration of n-3 and n-6 fatty acids for headache reduction in adults with migraine: randomized controlled trial.
Ramsden CE, Zamora D, Faurot KR, MacIntosh B, Horowitz M, Keyes GS, Yuan ZX, Miller V, Lynch C, Honvoh G, Park J, Levy R, Domenichiello AF, Johnston A, Majchrzak-Hong S, Hibbeln JR, Barrow DA, Loewke J, Davis JM, Mannes A, Palsson OS, Suchindran CM, Gaylord SA, Mann JD. Ramsden CE, et al. BMJ. 2021 Jun 30;374:n1448. doi: 10.1136/bmj.n1448. BMJ. 2021. PMID: 34526307 Free PMC article. Clinical Trial. - Targeted alterations in dietary n-3 and n-6 fatty acids improve life functioning and reduce psychological distress among patients with chronic headache: a secondary analysis of a randomized trial.
Ramsden CE, Faurot KR, Zamora D, Palsson OS, MacIntosh BA, Gaylord S, Taha AY, Rapoport SI, Hibbeln JR, Davis JM, Mann JD. Ramsden CE, et al. Pain. 2015 Apr;156(4):587-596. doi: 10.1097/01.j.pain.0000460348.84965.47. Pain. 2015. PMID: 25790451 Free PMC article. Clinical Trial. - Diet-induced changes in n-3- and n-6-derived endocannabinoids and reductions in headache pain and psychological distress.
Ramsden CE, Zamora D, Makriyannis A, Wood JT, Mann JD, Faurot KR, MacIntosh BA, Majchrzak-Hong SF, Gross JR, Courville AB, Davis JM, Hibbeln JR. Ramsden CE, et al. J Pain. 2015 Aug;16(8):707-16. doi: 10.1016/j.jpain.2015.04.007. Epub 2015 May 7. J Pain. 2015. PMID: 25958314 Free PMC article. - Balancing proportions of competing omega-3 and omega-6 highly unsaturated fatty acids (HUFA) in tissue lipids.
Bibus D, Lands B. Bibus D, et al. Prostaglandins Leukot Essent Fatty Acids. 2015 Aug;99:19-23. doi: 10.1016/j.plefa.2015.04.005. Epub 2015 Apr 18. Prostaglandins Leukot Essent Fatty Acids. 2015. PMID: 26002802 Review. - Association of diet and headache.
Razeghi Jahromi S, Ghorbani Z, Martelletti P, Lampl C, Togha M; School of Advanced Studies of the European Headache Federation (EHF-SAS). Razeghi Jahromi S, et al. J Headache Pain. 2019 Nov 14;20(1):106. doi: 10.1186/s10194-019-1057-1. J Headache Pain. 2019. PMID: 31726975 Free PMC article. Review.
Cited by
- Investigating the effects of co-supplementation with alpha-linolenic acid and L-carnitine on inflammatory status, oxidative stress, clinical symptoms, mental health and quality of life in women with migraine: a protocol for a randomized, triple-blind, placebo-controlled trial.
Golpour-Hamedani S, Bagherniy M, Khorvash F, Feizi A, Sharma M, Askari G. Golpour-Hamedani S, et al. Trials. 2024 Oct 8;25(1):666. doi: 10.1186/s13063-024-08500-3. Trials. 2024. PMID: 39380085 Free PMC article. - Beneficial effects of linoleic acid on cardiometabolic health: an update.
Jackson KH, Harris WS, Belury MA, Kris-Etherton PM, Calder PC. Jackson KH, et al. Lipids Health Dis. 2024 Sep 12;23(1):296. doi: 10.1186/s12944-024-02246-2. Lipids Health Dis. 2024. PMID: 39267068 Free PMC article. Review. - Dietary linoleic acid lowering alone does not lower arachidonic acid or endocannabinoids among women with overweight and obesity: A randomized, controlled trial.
Courville AB, Majchrzak-Hong S, Yang S, Turner S, Wilhite B, Ness Shipley K, Horneffer Y, Domenichiello AF, Schwandt M, Cutler RG, Chen KY, Hibbeln JR, Ramsden CE. Courville AB, et al. Lipids. 2023 Nov;58(6):271-284. doi: 10.1002/lipd.12382. Lipids. 2023. PMID: 38100748 Clinical Trial. - Association between diet and migraine characteristics: The role of dietary inflammatory index.
Khorsha F, Mirzababaei A, Ghodoosi N, Togha M, Yekaninejad MS, Askarpour M, Mirzaei K. Khorsha F, et al. Curr J Neurol. 2020 Apr 3;19(2):67-75. doi: 10.18502/cjn.v19i2.4943. Curr J Neurol. 2020. PMID: 38011387 Free PMC article. - Pharmacokinetics and Changes in Lipid Mediator Profiling after Consumption of Specialized Pro-Resolving Lipid-Mediator-Enriched Marine Oil in Healthy Subjects.
Irún P, Carrera-Lasfuentes P, Sánchez-Luengo M, Belio Ú, Domper-Arnal MJ, Higuera GA, Hawkins M, de la Rosa X, Lanas A. Irún P, et al. Int J Mol Sci. 2023 Nov 9;24(22):16143. doi: 10.3390/ijms242216143. Int J Mol Sci. 2023. PMID: 38003333 Free PMC article.
References
- Antonova M, Wienecke T, Olesen J, Ashina M. Prostaglandin E(2) induces immediate migraine-like attack in migraine patients without aura. Cephalalgia. 2012;32:822–33. - PubMed
- Antonova M, Wienecke T, Olesen J, Ashina M. Prostaglandins in migraine: update. Curr Opin Neurol. 2013;26:269–75. - PubMed
- Bigal ME, Rapoport AM, Lipton RB, Tepper SJ, Sheftell FD. Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: a comparison of chronic migraine with episodic migraine. Headache. 2003;43:336–42. - PubMed
- Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37:911–7. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- Z99 AA999999/Intramural NIH HHS/United States
- T32 AT003378/AT/NCCIH NIH HHS/United States
- T32-AT003378/AT/NCCIH NIH HHS/United States
- DK056350/DK/NIDDK NIH HHS/United States
- UL1RR025747/RR/NCRR NIH HHS/United States
- P30 DK056350/DK/NIDDK NIH HHS/United States
- UL1 RR025747/RR/NCRR NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical